← All organizations
Highest phase reached
Phase 2
First clinical trial
Jun 1, 2000Last known activity
May 1, 2017
Defunct as of Dec 2, 2019
Timeline
2000s
- Jun 1, 2000
Molecular NeuroImaging— Founded
2010s
- Dec 2, 2019
Molecular NeuroImaging— Defunct
Drugs by trial phase (28 distinct, 30 trials)
Phase 2 (8 own, 0 via acquisition)
Phase 1 (20 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Aphasia, Primary Progressive
- Brain Diseases
- Brain Injuries, Traumatic
- Chronic Traumatic Encephalopathy
- Dementia
- Frontotemporal Dementia
- Inflammation
- Motor Neuron Disease
- Multiple Sclerosis
- Neurodegenerative Diseases
- Parkinson Disease
- Pick Disease of the Brain
- Sclerosis
- Supranuclear Palsy, Progressive
- Tauopathies
Recent trials (46)
- NCT03142724Lead sponsorPhase 1May 1, 2017
- NCT03142724Overall official - principal investigatorPhase 1May 1, 2017
- NCT03082768Lead sponsorEarly Phase 1Mar 3, 2017
- NCT03082768Overall official - principal investigatorEarly Phase 1Mar 3, 2017
- NCT03058965Lead sponsorEarly Phase 1Nov 1, 2016
- NCT03080051Lead sponsorEarly Phase 1Aug 1, 2016
- NCT03080051Overall official - principal investigatorEarly Phase 1Aug 1, 2016
- NCT03876002Overall official - principal investigatorPhase 1Jun 28, 2016
- NCT03876002Lead sponsorPhase 1Jun 28, 2016
- NCT03071224Overall official - principal investigatorEarly Phase 1Jun 1, 2016
- NCT03071224Lead sponsorEarly Phase 1Jun 1, 2016
- NCT02531360Lead sponsorEarly Phase 1May 1, 2015
- NCT02531360Overall official - principal investigatorEarly Phase 1May 1, 2015
- NCT02531360Reponsible party - principal investigatorEarly Phase 1May 1, 2015
- NCT02370524Lead sponsorPhase 1Jan 1, 2015
Details
- Founded
- New Haven, CT, US Jun 1, 2000
- Last known activity
- May 1, 2017